# Camena Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/camena-bioscience

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.camenabio.com
- Total disclosed funding: $10M
- Latest round: Series A (Apr 28, 2023)
- Investors on record: 1

## About

Based in Cambridge, UK, and founded in 2016, Camena Biosciences Limited operates as a biotechnology company that provides genes to the pharmaceutical and biotechnology industries. The company was Co-founded by Steve Harvey (CEO) and Derek Stemple (CSO). In September 2025, Camena Bioscience Limited raised an undisclosed amount of venture funding from returning investor Mercia Asset Management, with participation from individual and other unspecified investors.

The company uses DNA synthesis technology and provides data on DNA analysis with its technology called gSynth™. This technology helps in the production of problematic DNA sequences and provides precise gene variant libraries for protein engineering and offers supply chain security.

The firm plans to use the July 2023 funding to further expand its operations and enhance its pioneering DNA synthesis platform, gSynth™.

## Funding rounds

- Series A, Apr 28, 2023, $10M — Mercia Asset Management

## Investors

- Mercia Asset Management (https://capitalatlas.ai/funds/mercia-asset-management) — Series A